The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back program, with a daily buy-back notification detailing the acquisition of 130,100 ordinary fully paid securities on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for neurodevelopmental disorders and other neurological conditions. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: -11.60%
Average Trading Volume: 781
Technical Sentiment Signal: Buy
Current Market Cap: $970.1M
See more insights into NEU stock on TipRanks’ Stock Analysis page.